AAAAI & ACAAI GUIDELINES Bundle (free trial)

Hereditary Angioedema

AAAAI & ACAAI GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/306000

Contents of this Issue

Navigation

Page 9 of 9

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies: orders@GuidelineCentral.com Copyright © 2014 All rights reserved AAAIHAE14053 Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbreviations ACE-I, angiotensin converting enzyme inhibitor; AE, angioedema; bid, twice a day; FDA, US Food and Drug Administration; g, gram; HAE, hereditary angioedema; INH, inhibitor; IV, intravenous; kg, kilogram; mg, milligrams; mL, milliliter; NL, normal; PO, by mouth; q3d, every 3 days; q3-4d, every 3 to 4 days; tid, 3 times a day Source Joint Task Force on Practice Parameters ( JTFPP), representing the American Academy of Allerg y, Asthma and Immunolog y; the American College of Allerg y, Asthma and Immunolog y; and the Joint Council of Allerg y, Asthma and Immunolog y. A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema. J Allerg y Clin Immunol 2013;131:1491-3. Grading System for Recommendations Category/Grade Definition Level of Evidence Ia Evidence from meta-analysis of randomized controlled trials Ib Evidence from at least one randomized controlled trial IIa Evidence from at least one controlled study without randomization IIb Evidence from at least one other type of quasi-experimental study III Evidence from non-experimental descriptive studies, such as comparative studies IV Evidence from expert committee reports or opinions or clinical experience of respected authorities or both Strength of Recommendation A Directly based on category I evidence B Directly based on category II evidence or extrapolated recommendation from category I evidence C Directly based on category III evidence or extrapolated recommendation from category I or II evidence D Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence LB (Lab Based)

Articles in this issue

Links on this page

Archives of this issue

view archives of AAAAI & ACAAI GUIDELINES Bundle (free trial) - Hereditary Angioedema